NGEN
Price
$1.42
Change
-$0.08 (-5.33%)
Updated
Oct 22 closing price
Capitalization
152.68M
21 days until earnings call
Intraday BUY SELL Signals
TNXP
Price
$5.13
Change
-$0.30 (-5.52%)
Updated
Oct 22 closing price
Capitalization
87.98M
18 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

NGEN vs TNXP

NGEN vs TNXP Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
NGEN vs. TNXP commentary
Oct 23, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NGEN is a StrongBuy and TNXP is a StrongBuy.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for NGEN with price predictions
Oct 22, 2026

NGEN's RSI Indicator is staying in oversold zone for 4 days

The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 22 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +2.84% 3-day Advance, the price is estimated to grow further. Considering data from situations where NGEN advanced for three days, in 212 of 258 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.

NGEN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

NGEN moved below its 50-day moving average on September 28, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for NGEN crossed bearishly below the 50-day moving average on October 02, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 81%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where NGEN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.

The Aroon Indicator for NGEN entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 22 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of 77 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.837) is normal, around the industry mean (2.973). P/E Ratio (-1.797) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).

The Tickeron Price Growth Rating for this company is 85 (best 1 - 100 worst), indicating slightly worse than average price growth. NGEN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NGEN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
a Summary for TNXP with price predictions
Oct 22, 2026

TNXP's RSI Oscillator is remaining in oversold zone for 22 days

The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

Following a +4.73% 3-day Advance, the price is estimated to grow further. Considering data from situations where TNXP advanced for three days, in 181 of 222 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.

TNXP may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The 10-day moving average for TNXP crossed bearishly below the 50-day moving average on September 21, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 9 of 10 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where TNXP declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

The Aroon Indicator for TNXP entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 49 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.396) is normal, around the industry mean (2.973). P/E Ratio (-0.392) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (5.176) is also within normal values, averaging (438.009).

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is 94 (best 1 - 100 worst), indicating slightly worse than average price growth. TNXP’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TNXP’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

FUNDAMENTALS RATINGS
NGEN vs TNXP: Fundamental Ratings
NGEN
TNXP
OUTLOOK RATING
1..100
5856
VALUATION
overvalued / fair valued / undervalued
1..100
77
Overvalued
49
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10098
PRICE GROWTH RATING
1..100
8594
P/E GROWTH RATING
1..100
22100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TNXP's Valuation (49) in the Pharmaceuticals Other industry is in the same range as NGEN (77) in the null industry. This means that TNXP’s stock grew similarly to NGEN’s over the last 12 months.

TNXP's Profit vs Risk Rating (100) in the Pharmaceuticals Other industry is in the same range as NGEN (100) in the null industry. This means that TNXP’s stock grew similarly to NGEN’s over the last 12 months.

TNXP's SMR Rating (98) in the Pharmaceuticals Other industry is in the same range as NGEN (100) in the null industry. This means that TNXP’s stock grew similarly to NGEN’s over the last 12 months.

NGEN's Price Growth Rating (85) in the null industry is in the same range as TNXP (94) in the Pharmaceuticals Other industry. This means that NGEN’s stock grew similarly to TNXP’s over the last 12 months.

NGEN's P/E Growth Rating (22) in the null industry is significantly better than the same rating for TNXP (100) in the Pharmaceuticals Other industry. This means that NGEN’s stock grew significantly faster than TNXP’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
NGENTNXP
RSI
ODDS (%)
Bullish Trend 1 day ago
90%
Bullish Trend 4 days ago
83%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
81%
N/A
Momentum
ODDS (%)
N/A
N/A
MACD
ODDS (%)
N/A
N/A
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
83%
Bearish Trend 1 day ago
90%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
83%
Bearish Trend 1 day ago
90%
Advances
ODDS (%)
Bullish Trend 18 days ago
82%
Bullish Trend 8 days ago
82%
Declines
ODDS (%)
Bearish Trend 1 day ago
82%
Bearish Trend 1 day ago
90%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
85%
Bullish Trend 1 day ago
72%
Aroon
ODDS (%)
Bearish Trend 1 day ago
77%
Bearish Trend 1 day ago
90%
COMPARISON
Comparison
Oct 23, 2026
Stock price -- (NGEN: $1.42 vs. TNXP: $5.43)
Brand notoriety: NGEN and TNXP are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: NGEN: 129% vs. TNXP: 129%
Market capitalization -- NGEN: $152.68M vs. TNXP: $87.98M
NGEN [@Biotechnology] is valued at $152.68M. TNXP’s [@Biotechnology] market capitalization is $87.98M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $135.64B. The average market capitalization across the [@Biotechnology] industry is $2.14B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

NGEN’s FA Score shows that 1 FA rating(s) are green while TNXP’s FA Score has 0 green FA rating(s).

  • NGEN’s FA Score: 1 green, 4 red.
  • TNXP’s FA Score: 0 green, 5 red.
According to our system of comparison, both NGEN and TNXP are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NGEN’s TA Score shows that 4 TA indicator(s) are bullish while TNXP’s TA Score has 3 bullish TA indicator(s).

  • NGEN’s TA Score: 4 bullish, 4 bearish.
  • TNXP’s TA Score: 3 bullish, 3 bearish.
According to our system of comparison, both NGEN and TNXP are a good buy in the short-term.

Price Growth

NGEN (@Biotechnology) experienced а -12.35% price change this week, while TNXP (@Biotechnology) price change was -15.16% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.17%. For the same industry, the average monthly price growth was -18.21%, and the average quarterly price growth was -15.24%.

Reported Earning Dates

NGEN is expected to report earnings on Nov 12, 2026.

TNXP is expected to report earnings on Nov 09, 2026.

Industries' Descriptions

@Biotechnology (-1.17% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
NGEN
Daily Signal:
Gain/Loss:
TNXP
Daily Signal:
Gain/Loss:
Interact to see
Advertisement

TNXP and

Correlation & Price change

A.I.dvisor indicates that over the last year, TNXP has been closely correlated with ICU. These tickers have moved in lockstep 77% of the time. This A.I.-generated data suggests there is a high statistical probability that if TNXP jumps, then ICU could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To TNXP
1D Price
Change %
TNXP100%
-5.52%
ICU - TNXP
77%
Closely correlated
-10.09%
CADL - TNXP
42%
Loosely correlated
+0.12%
ZURA - TNXP
40%
Loosely correlated
-14.53%
FDMT - TNXP
40%
Loosely correlated
-6.10%
RCKT - TNXP
40%
Loosely correlated
+5.00%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
UTF26.080.20
+0.77%
Cohen & Steers Infrastructure Fund
BEMB51.020.16
+0.31%
iShares J.P. Morgan Broad USD Emerging Markets Bond ETF (BEMB)
IBID25.900.03
+0.12%
iShares iBonds Oct 2027 Term TIPS ETF (IBID)
MYHE23.64-0.02
-0.08%
State Street My2031 High Yield Corporate Bond ETF (MYHE)
NTSI46.31-0.11
-0.23%
WisdomTree International Efficient Core Fund (NTSI)